Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure-Reference-Cited by-同舟云学术

Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure

Published:2006-01 Issue:1 Volume:46 Page:37-44
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Paccaly Anne,Frick Annke,Rohatagi Shashank,Liu Jingli,Shukla Umesh,Rosenburg Ronald,Hinder Markus,Jensen Bradford K.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference11 articles.

1. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation;Bertrand;Eur Heart J.,2002

2. Clinician update: direct thrombin inhibitors in acute coronary syndromes;Wykrzykowska;J Thromb Thrombolysis.,2003

3. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation;Dyke;Circulation.,2002

4. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux);Samama;Thromb Res.,2003

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry;eLife;2022-03-23

2. The Fight against COVID-19 on the Multi-Protease Front and Surroundings: Could an Early Therapeutic Approach with Repositioning Drugs Prevent the Disease Severity?;Biomedicines;2021-06-23

3. Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry;2021-04-01

4. Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties;Chemical Science;2021

5. Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales;Current Topics in Medicinal Chemistry;2016-03-01